FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3181280617> ?p ?o ?g. }

• W3181280617 abstract "Tumor cells engage in bidirectional interactions with stroma and immune cells to promote disease progression and immune evasion. Stroma-specific gene signatures have been associated with outcome in diffuse large B-cell lymphoma (DLBCL), but their immunobiology has been understudied.To characterize the stromal landscape in lymphoma, we performed high-dimensional imaging mass cytometry analysis of the major stroma subsets and revealed a marked expansion and remodeling of the immuno-specialized fibroblastic reticular cells (FRCs) in human DLBCL biopsies (n=53). The FRC network was similarly remodeled in tumors from the IμBcl6 transgenic model of lymphoma, and aberrant fibroblasts were in close proximity to cancer cells.Modelling the interactions between murine and patient FRCs and tumor cells, using 2D and 3D cultures, showed that lymphoma drives the acquisition of an inflammatory-like, pro-tumoral (upregulation of fibroblast activating protein-α, FAP) phenotype and associated functional capabilities. Comparative bulk transcriptomic analysis revealed that lymphoma-FRCs undergo transcriptional reprogramming and activate gene pathways associated with inflammatory responses. Moreover, single-cell RNA-seq revealed an expansion of activated FRC clusters expressing B cell supporting genes, while T cell-associated FRCs were contracted. Altered chemokine signaling pathways in DLBCL-FRCs were functionally linked to reduced attraction of T cells and impeded migration along the lymphoma-reticular network. Moreover, lymphoma-FRCs upregulated expression of inhibitory PD-1 ligands that reduced the anti-tumor cytolytic activity of CD8+ T cells, a T cell bispecific antibody (CD20-TCB, glofitamab) and anti-CD19 CAR T cells in our coculture models.To overcome the immunosuppressive activity of DLBCL-FRCs, we investigated the use of CD20-TCB in combination with stroma-targeting immunocytokine fusion protein drug (FAP-IL2v, RG7461) or costimulatory fusion protein (FAP-4-1BBL, RG7827). Functional cytotoxicity assays using human and murine primary DLBCL patient samples revealed that both stroma-targeting drugs paired effectively with the CD20-TCB to enhance the cytotoxic activity of autologous CD8+ T cells. In addition, the ability of immune-/stroma- targeted combination immunotherapy to trigger anti-tumor activity and CD8+ T cell retention within the FRC-TME was demonstrated using 3D precision-cut lymph node slice-based organotypic cultures of DLBCL and other B cell malignancies.In conclusion our data reveal that lymphoma cells actively reprogram FRCs that acquire altered immunoregulatory function which prevents effective T cell motility and suppresses the anti-tumor function of cytolytic T cells. Importantly, we demonstrate that combination immunotherapy incorporating fibroblast-targeting fusion proteins could effectively recover anti-tumor T cell activity.Citation Format: Benedetta Apollonio, Nedyalko Petrov, Filomena Spada, Peter Jarvis, Domenico Cozzetto, Shichina Kannambath, David Kuo, Mansoor Saqui, Rose-Marie Amini, Gunilla Enblad, Graham Charlotte, Reuben Benjamin, Anna Vardi, Elisabeth Phillips, Jon Salisbury, Eric N. Olson, Brian Fox, Patrick Hagner, Anita Gandhi, Ruth F. Jarrett, Sylvia Herter, Marina Bacac, Christina Klaus, Christian Klein, Alexander Deutsch, Alan G. Ramsay. Stroma-immune landscape in lymphoma: new mechanisms of immunosuppression and therapeutic targeting [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 3165." @default.
• W3181280617 created "2021-07-19" @default.
• W3181280617 creator A5002292400 @default.
• W3181280617 creator A5002520769 @default.
• W3181280617 creator A5004443381 @default.
• W3181280617 creator A5004539672 @default.
• W3181280617 creator A5006906885 @default.
• W3181280617 creator A5007401286 @default.
• W3181280617 creator A5010450706 @default.
• W3181280617 creator A5010861766 @default.
• W3181280617 creator A5017804574 @default.
• W3181280617 creator A5018125274 @default.
• W3181280617 creator A5022361583 @default.
• W3181280617 creator A5024719106 @default.
• W3181280617 creator A5026914621 @default.
• W3181280617 creator A5043395223 @default.
• W3181280617 creator A5056210516 @default.
• W3181280617 creator A5064854468 @default.
• W3181280617 creator A5065347822 @default.
• W3181280617 creator A5065549220 @default.
• W3181280617 creator A5067162282 @default.
• W3181280617 creator A5078956440 @default.
• W3181280617 creator A5082541805 @default.
• W3181280617 creator A5083412701 @default.
• W3181280617 creator A5084182062 @default.
• W3181280617 creator A5086794693 @default.
• W3181280617 creator A5087243215 @default.
• W3181280617 creator A5090929242 @default.
• W3181280617 date "2021-07-01" @default.
• W3181280617 modified "2023-10-14" @default.
• W3181280617 title "Abstract 3165: Stroma-immune landscape in lymphoma: new mechanisms of immunosuppression and therapeutic targeting" @default.
• W3181280617 doi "https://doi.org/10.1158/1538-7445.am2021-3165" @default.
• W3181280617 hasPublicationYear "2021" @default.
• W3181280617 type Work @default.
• W3181280617 sameAs 3181280617 @default.
• W3181280617 citedByCount "0" @default.
• W3181280617 crossrefType "proceedings-article" @default.
• W3181280617 hasAuthorship W3181280617A5002292400 @default.
• W3181280617 hasAuthorship W3181280617A5002520769 @default.
• W3181280617 hasAuthorship W3181280617A5004443381 @default.
• W3181280617 hasAuthorship W3181280617A5004539672 @default.
• W3181280617 hasAuthorship W3181280617A5006906885 @default.
• W3181280617 hasAuthorship W3181280617A5007401286 @default.
• W3181280617 hasAuthorship W3181280617A5010450706 @default.
• W3181280617 hasAuthorship W3181280617A5010861766 @default.
• W3181280617 hasAuthorship W3181280617A5017804574 @default.
• W3181280617 hasAuthorship W3181280617A5018125274 @default.
• W3181280617 hasAuthorship W3181280617A5022361583 @default.
• W3181280617 hasAuthorship W3181280617A5024719106 @default.
• W3181280617 hasAuthorship W3181280617A5026914621 @default.
• W3181280617 hasAuthorship W3181280617A5043395223 @default.
• W3181280617 hasAuthorship W3181280617A5056210516 @default.
• W3181280617 hasAuthorship W3181280617A5064854468 @default.
• W3181280617 hasAuthorship W3181280617A5065347822 @default.
• W3181280617 hasAuthorship W3181280617A5065549220 @default.
• W3181280617 hasAuthorship W3181280617A5067162282 @default.
• W3181280617 hasAuthorship W3181280617A5078956440 @default.
• W3181280617 hasAuthorship W3181280617A5082541805 @default.
• W3181280617 hasAuthorship W3181280617A5083412701 @default.
• W3181280617 hasAuthorship W3181280617A5084182062 @default.
• W3181280617 hasAuthorship W3181280617A5086794693 @default.
• W3181280617 hasAuthorship W3181280617A5087243215 @default.
• W3181280617 hasAuthorship W3181280617A5090929242 @default.
• W3181280617 hasBestOaLocation W31812806171 @default.
• W3181280617 hasConcept C16930146 @default.
• W3181280617 hasConcept C203014093 @default.
• W3181280617 hasConcept C204232928 @default.
• W3181280617 hasConcept C2776107976 @default.
• W3181280617 hasConcept C2779338263 @default.
• W3181280617 hasConcept C502942594 @default.
• W3181280617 hasConcept C52124034 @default.
• W3181280617 hasConcept C86803240 @default.
• W3181280617 hasConcept C8891405 @default.
• W3181280617 hasConceptScore W3181280617C16930146 @default.
• W3181280617 hasConceptScore W3181280617C203014093 @default.
• W3181280617 hasConceptScore W3181280617C204232928 @default.
• W3181280617 hasConceptScore W3181280617C2776107976 @default.
• W3181280617 hasConceptScore W3181280617C2779338263 @default.
• W3181280617 hasConceptScore W3181280617C502942594 @default.
• W3181280617 hasConceptScore W3181280617C52124034 @default.
• W3181280617 hasConceptScore W3181280617C86803240 @default.
• W3181280617 hasConceptScore W3181280617C8891405 @default.
• W3181280617 hasLocation W31812806171 @default.
• W3181280617 hasOpenAccess W3181280617 @default.
• W3181280617 hasPrimaryLocation W31812806171 @default.
• W3181280617 hasRelatedWork W1993869378 @default.
• W3181280617 hasRelatedWork W2551414968 @default.
• W3181280617 hasRelatedWork W2730739450 @default.
• W3181280617 hasRelatedWork W2995903778 @default.
• W3181280617 hasRelatedWork W3010976621 @default.
• W3181280617 hasRelatedWork W3098613608 @default.
• W3181280617 hasRelatedWork W4213317562 @default.
• W3181280617 hasRelatedWork W4284965464 @default.
• W3181280617 hasRelatedWork W4361823855 @default.
• W3181280617 hasRelatedWork W4367852177 @default.
• W3181280617 isParatext "false" @default.
• W3181280617 isRetracted "false" @default.
• W3181280617 magId "3181280617" @default.
• W3181280617 workType "article" @default.